

Jimmy Yen-Chu Lin (林彥竹)

CEO, Insilico Medicine Taiwan

Email: jimmy.lin@insilico.com; yen-chu.lin@alumni.ethz.ch Phone (O): (+886)2 27577168 ext24

Current Position

10/2019-present **Chief Executive Officer**, Insilico Medicine Taiwan

- Built up a sophisticated team with 15+ interdisciplinary scientists (AI, CADD, Chemistry, Biology), business development and administrative staffs focus in applying AI for end-to-end drug discovery.
- Secured several multimillions drug discovery deals with top-tiered pharmaceutical companies and biotechs.
- Oversaw research teams for internal technology development as well as external partnership projects ranging from AI algorithms development, target identification to drug discovery.
- Played a major role in Insilico Medicine round B and round C fundraising activities. Secured multimillions fund from TW investors.
- Executive management members of Insilico Medicine.

Experience

10/2018-09/2019 **Chief Scientific Officer**, Insilico Medicine Taiwan

- Built up a research team with AI, Chemistry, CADD and Biology expertise.
- Developed automatic molecular design workflow as an inhouse platform.
- Led scientific and business negotiation with pharma partners.
- Participated in due diligence calls with investors to introduce Insilico technologies.
- Initiated multiple internal drug discovery programs applying AI techniques.

10/2014-09/2018 **Research Fellow**, p53 lab, A*STAR, Singapore

- Developed yeast surface display techniques and screening protocols.
- Constructed diverse peptides, Fab, scFv and nanobody libraries on yeast surface to screen for inhibitors against different targets.
- Expressed proteins of interest in different expression systems and established robust protocols for batch expression.
- Led research collaborations with pharma partners in peptide and antibody development.

06/2015-08/2015 **Visiting Scientist**, Department of stem cell and regenerative biology, Harvard University, USA

- Established stapled peptides synthesis and purification protocols.
- Established yeast surface display techniques and screening cascades.

Education

- 08/2011-09/2014 **Ph.D., Pharmaceutical Sciences, ETH Zürich, Switzerland**
09/2007-07/2009 **M.S., Pharmacology, National Taiwan University, Taiwan**
09/2003-07/2007 **B.S., Pharmacy, minor in chemistry, National Taiwan University, Taiwan**

Selected Awards & Scholarships

- 2017 Young investigator best poster award, 3rd Peptides and Proteins Symposium Singapore
2013 Studying Abroad Scholarship, Ministry of Education, Taiwan
2012 Studying Abroad Scholarship, Ministry of Education, Taiwan
2009 Group leader of civilian military serviceman, Food and Drug Administration, Ministry of Health and Welfare, Taiwan
2007 Outstanding student, Department of Pharmacy, National Taiwan University, Taiwan
2007 Qualified in the national exam for pharmacist professional license
2005 Excellent performance in Summer Research Camp, College of Medicine, National Taiwan University, Taiwan

Publications

- Lee, K., Yang, A., **Lin, Y. C.**[#], Reker, D., Bemardes, G.J.L. and Rodrigues, T.[#]; Combating small molecule aggregation with machine learning. (2021) *Cell Reports Phys Sci.* 2, 9, 22 September 2021, 100573 ([#]co-corresponding authors)
- Vanhaelen, Q., **Lin, Y. C.**, and Zhavoronkov, A.; The advent of generative chemistry and biology. (2020) *ACS Med. Chem. Lett.* 11, 1496-1505
- Kao, P.Y., Kao, S.M., Huang, N.L. and **Lin, Y. C.**; Toward robust drug-target interaction prediction via ensemble modeling and transfer learning. (2021) *IEEE International Conference on Bioinformatics and Biomedicine (BIBM)*, pp. 2384-2391, doi: 10.1109/BIBM52615.2021.9669729.
- Fossi, Y.*^{*}, **Lin, Y. C.***^{*}, Shimin, J., Ramlan, S.R., Hew, K., Engman, A.H., Nordlund, P., Goh, M., Thean, D., Lane, D.P., Asial, I. and Brown, C.J.; Engineering disulphide-free autonomus antibody VH domains to modulate intracellular pathway. Preprint available at Research Square (2022) <https://doi.org/10.21203/rs.3.rs-244469/v2> (*co-first authors)
- Fossi, Y.*^{*}, NG, S.*^{*}, **Lin, Y. C.***^{*}, Shimin, J., Ramlan, S.R., Lama, D., Verma, CS., Asial, I. and Brown, C.J.; Development of a novel peptide aptamer that interacts with the eIF4E capped-mRNA binding site using peptide epitope linker evolution (PELE). *RSC Chem. Biol.*, 2022, Advance Article. DOI: 10.1039/D2CB00099G
- Zhavoronkov, A., Zagribelnyy, B., Zhebrak, A., Aladinskiy, V., Terentiev, V., Vanhaelen. Q., Bezrukov, D., ... **Lin, Y.C.** et al.; (2020) Potential non-covalent SARS-CoV-2 3C-like protease inhibitors designed using generative deep learning approaches and reviewed by human medicinal chemist in virtual reality. *ChemRxiv* (2020). doi:10.26434/chemrxiv.12301457.v1
- Pillong, M., Schneider, P., Hiss, J. A., **Lin, Y. C.**, Posselt, G., Pfeiffer, B., Altmann, K.-H., Blatter, M., Wessler, S. and Schneider, G.; Rational design of self-assembling membrane-pore-forming peptides. (2017) *Small.* 13, 1701316.
- **Lin, Y. C.**, Lim, Y. F., Russo, E., Schneider, P., Bolliger, L., Edenharter, A., Altmann, K.-H., Halin,

- C., Hiss, J. A. and Schneider, G.; Multidimensional design of anticancer peptides. (2015) *Angew. Chem. Int. Ed.* 54, 10370-10374.
- Rodrigues, T., **Lin, Y. C.**, Hartenfeller, M., Renner, S., Lim, Y. F. and Schneider, G.; Repurposing *de novo* designed entities reveals phosphodiesterase 3B and cathepsin L modulators. (2015) *Chem. Commun.* 51, 7478-7481
 - **Lin, Y. C.**, Hiss, J. A., Schneider, P., Thelesklaf, P., Lim, Y. F., Pillong, M., Koehler, F. M., Dittrich, P., Halin, C., Wessler, S. and Schneider, G.; Piloting membrane-lytic activities of designer peptides by a self-organizing map. (2014) *ChemBioChem.* 15(15), 2225-31.
 - Rodrigues, T., Kudoh, T., Roudnicky, F., Lim, Y. F., **Lin, Y. C.**, Koch, C. P., Seno, M., Detmar, M. and Schneider, G.; Steering target selectivity and potency by fragment-based *de novo* drug design. (2013) *Angew. Chem. Int. Ed.* 52, 10006-10009. (VIP paper)
 - Schneider, G., **Lin, Y.C.**, Koch, C. P., Pillong, M., Perna, A. M., Reutlinger, M. and Hiss, J. A.; Adaptive peptide design. (2013) *Chimia* 67, 859-863.
 - Weng, Y.C., Chuang, S.T., **Lin, Y.C.**, Chuang, C.F., Chi, T.C., Chiu, H.L., Kuo, Y.H. and Su, M.J.; Caffeic acid phenylethyl amide protects against the metabolic consequences in diabetes mellitus induced by diet and streptozocin. (2012) *Evidence-Based Complementary and Alternative Medicine.* 2012:984780
 - Weng, Y.C., Chi, T.C., **Lin, Y.C.**, Kuo, Y.H. and Su, M.J.; Antihyperglycemic effect of a caffeamide derivative, KS370G, in normal and diabetic mice. (2010) *J. Agric. Food Chem.*, 58, 10033-8

Patents

- Yang, Y.C., Yeh, T.L. and **Lin, Y.C.**; Structure-based deep generative model for binding site descriptors extraction and *de novo* molecular generation. Filing the provisional patent application with USPTO.